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ABSTRACT
Background: Millions of individuals are affected by cardiovascular disease (CVD). Many of
these require surgical intervention; some of which undergo cardiopulmonary bypass (CPB).
Unfortunately, refractory hypotension is a common occurrence when CPB is utilized; which leads
to increased morbidity and mortality.
Aim: The traditional treatment for post-CPB vasoplegia is high doses of vasopressors, but this
treatment option has been proven to be associated with tissue ischemia. The purpose of this
scholarly project is to determine if prophylactic administration of Methylene Blue (MB) is a
viable treatment option for post-CPB vasoplegia, as MB can prevent smooth muscle vasodilation
while avoiding the adverse effects of vasopressors at high doses.
Results: MB appears to be a promising treatment option for the refractory hypotension that can
follow the post-CPB period due to its ability to disrupt the Nitric Oxide pathway.
Discussion: Methylene Blue has proven to be an effective treatment for refractory hypotension
after the discontinuation of CPB on various cases, and it has a wide margin of safety. However,
most of its use is limited to last-line rescue therapy rather than prophylaxis.
Educational Project: An educational module was created to challenge conventional clinical
thinking. An informative PowerPoint presentation was disseminated to anesthesia providers along
with a Pre-Test to assess baseline knowledge, and a Post-Test to determine if learning had
occurred. Clinicians were also asked about their likelihood to incorporate MB into their practice.
Conclusion: Methylene Blue is an old drug with great new potential. However, the number of
studies that focus on prophylaxis is limited. More research is necessary to establish new practice
guidelines that could provide great benefit to a large patient population.
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INTRODUCTION
Problem Description
Cardiovascular disease (CVD) is the leading cause of death worldwide. Approximately
31% of all mortality is attributed to CVD.1 In the United States, heart failure afflicts over five
million individuals and over sixty million have been diagnosed with hypertension (HTN).1,2 It is
estimated that a staggering $316,000,000,000 is spent on treatment for CVD annually.1 Although
the school of thought behind the management of disease states in America is to apply
interventions from least intrusive to most invasive, lifestyle modifications and pharmacology do
not suffice in every scenario. Indeed, many of these patients require surgery to improve quality of
life, and in various instances, to survive.
Anesthesia providers, such as Certified Registered Nurse Anesthetists (CRNAs), provide
healthcare services to patients with cardiovascular disease often because the risk factors are
numerous and quite common. These factors include advanced age, HTN, obesity, dyslipidemia,
poor socioeconomic status, unbalanced diets that are high in fats and sodium, sedentary lifestyle,
and smoking.3 A proficient CRNA must be aware of the clinical implications linked to CVD
management as some patients require major surgery with the use of cardiopulmonary bypass
(CPB); a treatment modality that is known to cause postoperative refractory hypotension in 5% 25% of patients.4
Background
Cardiopulmonary bypass is a treatment modality in which a device temporarily takes over
the function of the heart and lungs during surgery. CPB is a continuous circuit that diverts blood
from the surgical field to provide optimal operational exposure and conditions whilst maintaining
the patient at near-physiological hemodynamic balance.1 This technique may be employed for
surgical interventions of the heart, lungs, or major blood vessels. At a glance, the concept of
cardiopulmonary bypass seems like a medical marvel, but it is not without setbacks and major
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potential risks. A potentially devastating consequence of complex cardiovascular surgery is the
development of vasoplegic syndrome after CPB is discontinued.
Vasoplegic syndrome (VS) “is characterized by significant arterial hypotension, normal
or high cardiac output, low systemic vascular resistance, and increased requirements for
intravenous volume and vasopressors.”5 VS is linked to the release of cytokines, argininevasopressin system impairment, endothelial dysfunction, decreased myogenic reactivity to
catecholamines, and increased nitric oxide (NO) production; all of which lead to marked vascular
smooth muscle relaxation.6 Of note, CPB is associated with increased NO levels proportional to
the total time on bypass.4
Due to the nature of cardiovascular disease, patients scheduled for surgery may also
present with additional compounding factors that will make VS post-CBP more likely such as the
use of preoperative beta-blockers (BB), angiotensin-converting enzyme (ACE) inhibitors,
calcium channel blockers (CCB), low ejection fractions, and other comorbidities.4 Furthermore,
procedures that employ CBP require heparin administration and consequent protamine
administration which may produce profound vasodilation that is refractory to vasopressors and
fluid resusitation.7,1
Significance of the Problem
Vasoplegic syndrome after cardiopulmonary bypass places a great burden on the
American healthcare system due to increased morbidity and mortality in the aforementioned
patient population. “Mortality rates for patients experiencing persistent vasoplegia for 36 to 48
hours range from 25% to 28.6%.”7 Moreover, individuals experiencing VS require acute care
with potent vasopressor therapy which comes with a hefty price tag. In 2010, the estimated daily
cost of hospital stays in an intensive care unit (ICU) was $4,300.8 Furthermore, the average ICU
length of stay (LOS) in the United States is 3.8 days, and two of the top three leading causes of
death in ICUs are cardiovascular failure and multiorgan failure.8 Lastly, the traditional treatment
for VS – phenylephrine and norepinephrine – have serious adverse effects at high doses including

7
organ hypoperfusion and ischemic extremities; both of which can lead to tissue necrosis, acute
renal failure, and metabolic acidosis.7
PICO Question
Do surgical patients undergoing cardiopulmonary bypass experience less postoperative
hypotension with prophylactic administration of Methylene Blue than patients that do not receive
Methylene Blue prophylactically?
METHODOLOGY
Systematic Review Rationale
Three glaring knowledge gaps exist in the clinical community in regard to the treatment
of VS, and they are as follows. The use of preoperative ACE inhibitors presents a challenge to the
management of hypotension that typically follows the discontinuation of CPB. When ACE
inhibitors are taken within 8 to 24 hours of general anesthesia, hypotension is probable.2
However, there is no general consensus or guideline for continuing or withholding ACE
inhibitors in the preoperative period, which makes patient management challenging.2
Secondly, the role of the endothelial glycocalyx after CPB is also poorly understood. It is
proposed that elements of the glycocalyx regulate vascular tone, and that would present a new
avenue for treatment of VS. Unfortunately, there are no available therapeutic interventions that
target the endothelial glycocalyx.4 Lastly, methylene blue (MB) has recently gained widespread
attention as an adjunct for the treatment of VS post-CBP, but there are no set guidelines for the
timing or dosage of its administration.7
Objective of Proposed Solution
Methylene Blue is well known as the treatment of choice for methemoglobinemia, but its
use should not be limited to just one condition.9 The author of this scholarly paper proposes that
MB should be prophylactically administered preoperatively to patients scheduled for complex
cardiovascular surgery to prevent vasoplegic syndrome after cardiopulmonary bypass. Methylene
Blue’s “proposed mechanism of action is prevention of smooth muscle vasodilation due to
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blockade of nitric oxide synthase.”10 Furthermore, “MB is a competitive inhibitor of guanylate
cyclase that decreases intracellular levels of cyclic CMP. It binds to the heme moiety of the
enzyme and inhibits cyclic GMP production increasing vascular tone.”11 Additionally, it has
catecholamine-sparing effects that prevents the adverse consequences that accompany
vasopressors at high doses.7
Refractory hypotension that ensues after cardiopulmonary bypass can have a significant
impact on the wellbeing of cardiovascular patients and on the healthcare system as a whole. The
traditional treatment options of phenylephrine, norepinephrine, and fluid resuscitation are not
always effective and come with great risks. Methylene Blue, with a wide therapeutic safety
profile, has proven to be effective in the treatment of VS post-CBP by significantly increasing
mean arterial pressure, and decreasing the need for vasopressors and fluid resuscitation.7,11
Search Strategy and Sources
In order to carry out a literature review, the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) was used for guidance.12 The platforms in which the
searches were conducted were the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), PubMed Central, and Embase. The keywords or terms utilized were as follows:
methylene blue, cardiopulmonary bypass, CPB, hypotension, refractory hypotension, low blood
pressure, vasoplegia, refractory vasoplegia, vasoplegic syndrome, prophylaxis, prophylactic
methylene blue, prevention, preoperative methylene blue, post-CPB hypotension, and post-CPB
vasoplegia. The Boolean operators employed were: (methylene blue) AND (cardiopulmonary
bypass OR CPB), (methylene blue) AND (vasopleg*), and (methylene blue) AND (hypotension
OR low blood pressure). This search strategy yielded 77 results on CINAHL, 481 results on
PubMed Central, and 134 results on Embase; for a total of 692 articles.
Study Selection and Screening
With a grand total of 692 possible articles, the author of this scholarly paper began the
selection process by reviewing titles and abstracts that were applicable to the original PICO
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question. This process trimmed down the number of viable articles to 67. From that point
inclusionary criteria helped further hone-in on the appropriate data: articles published between
1994 and 2020, articles published in English, adult test subjects, surgery that required
cardiopulmonary bypass, cases in which refractory hypotension followed the post-operative
period, and administration of Methylene Blue for the purpose of hemodynamic stability only.
Exclusionary criteria included: articles in languages other than English, pediatrics, animal
subjects, methylene blue administration for purposes other than hemodynamic stability, cardiac
surgeries without the use of cardiopulmonary bypass, emergency procedures, and ASA
classifications higher than 4.

The aforementioned criteria are displayed in tabular form below in Table 1.
Table 1. Inclusion and Exclusion Criteria
Inclusion
Population:
• Adults
• Cardiovascular patients
• Patients with refractory hypotension after CPB
Type of procedure:
• Surgery with cardiopulmonary bypass
Intervention:
• Methylene Blue administration
Outcomes:
• Measurements of hemodynamic parameters postCPB
Type of study:
• RCTS
• Retrospective observational studies
• Literature reviews
• Publication dates from 1994 to 2020
• Articles published in English

Exclusion
Population:
• Animals
• Pediatrics
• Parturients
• ASA level above 4
Type of procedure:
• Surgery without
cardiopulmonary bypass
• Emergency surgeries
Intervention:
• No administration of
Methylene Blue
• Administration of MB in
combination with other
pharmacologic agents
Outcomes:
• No hemodynamic
measurements post-CPB
Type of study:
• Level IV articles
• Level V articles
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Identification

Figure 1. Prisma Flow Diagram

Records identified through
database searching
(n = 692)

Additional records identified
through other sources
(n = 0)

Eligibility

Screening

Records after duplicates removed
(n = 650)

Records screened
(n = 67)

Records excluded
(n = 59)

Full-text articles assessed
for eligibility
(n = 8)

Full-text articles excluded,
with reasons
(n = 0)

Included

Studies included in
quantitative synthesis
(meta-analysis)
(n = 7)
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Data Analysis
The quality of the articles was evaluated with the Johns Hopkins Nursing EvidenceBased Practice evidence appraisal tool.13 Strength of evidence falls under one of five different
levels. Level I, the highest level of evidence is reserved for experimental studies, randomized
controlled trials (RCTS), systematic review of RCTS, and explanatory mixed method designs that
include only Level I quantitative studies.13 Level II accommodates quasi-experimental studies;
systematic review of RCTS and quasi-experimental studies, or quasi-experimental studies only;
and explanatory mixed method designs that only include Level II quantitative studies.13 Level III
includes nonexperimental studies; systematic review of a combination of RCTs, quasiexperimental and nonexperimental studies, or nonexperimental studies only; qualitative studies or
meta-synthesis; exploratory mixed-method studies; and explanatory mixed method designs that
include only Level III quantitative studies.13 Further down the line are levels that do not enjoy the
strength of evidence of the aforementioned categories. Opinions of respected authorities and
reports of nationally recognized committees make up Level IV.13 Level V includes evidence
obtained from literature reviews or case reports, and opinions of nationally recognized experts
based on experience.13
Evaluation of Literature
The scholarly articles that were reviewed spanned from publications from 1994 through
2018. The final selection includes four Level I randomized controlled trials (RCTs), one Level III
observational study without a control group, one Level III retrospective observational study
without a control group, and one Level II literature review. After combing through the data, the
following focal points arose.
Vasoplegia, or vasoplegic syndrome (VS), is a term that describes distinct clinical
features that are associated with cardiopulmonary bypass: normal or high cardiac output (CO),
hypotension, decreased systemic vascular resistance (SVR), and high requirements of
vasopressors and fluid resuscitation. Its incidence lies between 5% to 25% after cardiac surgery. 7
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According to Leyh et al. “norepinephrine-refractory systemic vasoplegia is defined as a mean
arterial blood pressure lower than 60 mm Hg, a cardiac output greater than 4.0 L/min, low SVR
(<600 dyne) under intravenous norepinephrine infusion (0.5 mcg/kg/min).” 14
The traditional treatments for the hypotension that usually follows the discontinuation of
cardiopulmonary bypass (CPB) are phenylephrine and norepinephrine infusions. Prompt
intervention is necessary because the mortality rates from VS that persists for up to 48 hours lie
between the 25% and 28.6% range. 15 Unfortunately, high doses of vasopressors are often used to
prevent mortality via VS and these medications are not without serious potential adverse effects.
Both phenylephrine and norepinephrine can cause organ hypoperfusion and ischemic extremities
at high doses. Additionally, these complications can lead to tissue necrosis, acute renal failure,
and metabolic acidosis. 7
The etiology of vasoplegia is multifactorial. Many cardiac surgical patients have different
factors that place them at risk of developing VS, and CBP compounds the issue through increased
production of nitric oxide. 7 “Nitric oxide is an important vasodilatory mediator that is
synthesized from L-arginine by nitric oxide synthase (NOS) in endothelial cells. Nitric oxide
synthase increases levels of NO, which then diffuses into the vascular smooth muscle and
interacts with the enzyme guanylyl cyclase. This enzyme is important in the conversion of
guanylyl triphosphate to cyclic guanylyl monophosphate (cGMP). Serving as a second
messenger, cGMP activates protein kinases responsible for the phosphorylation of calcium ion
(Ca2+) channels, inhibiting influx of Ca2+ into smooth muscle and promoting Ca2+ sequestration
into the sarcoplasmic reticulum. The result of this signaling pathway is a decrease in cytoplasmic
calcium that prevents contraction of vascular smooth muscle.” 16 It is proposed that CPB
propagates this response when blood comes in contact with the cardiopulmonary bypass circuit. 7
RESULTS
Methylene Blue (MB) is traditionally used to treat methemoglobinemia, visualize ureters
in urology procedures, and to identify specific endocrine tissue. 7 However, MB has gained recent
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clinical interest as a treatment option for VS post-CPB due to its ability to disrupt the NO
pathway. 14 All articles reviewed demonstrated promising patient outcomes with no adverse
effects. In 2003, Leyh et al. assessed 54 patients that received 2mg/kg of intravenous MB to treat
VS post-CPB. “Immediately after MB infusion, clinically significant increases in MAP and SVR
combined with a significant decrease in NE dosage were seen in 92.4% of patients. 14 In an RCT
in 2012, Cho et al. demonstrated that a single bolus of prophylactic MB yielded greater
hemodynamic stability for the patient population in question. 21 patients (the experimental group)
received 2mg/kg of IV MB before the initiation of CPB, and the entire experimental group
required fewer colloid infusions than the control. 17
In the 2005 RCT by Ozal et al. 50 patients (the experimental group) were preoperatively
administered 2mg/kg of IV MB. The experimental group attained higher intraoperative SVR,
reduced NE infusion requirements, lower incidence of required inotropic support, decreased need
for fluid resuscitation, and reduced hospital length of stay. 18 Maslow’s RCT of 2006
administered 3mg/kg of IV MB to its control group of 15 patients at the onset of cardiopulmonary
bypass. The experimental group attained increased SVR and MAP when compared to the control.
The control group also required greater amounts of NE. 15
In an extensive literature review, Evora et al. reaffirmed that Methylene Blue is effective
in cases of NO up-regulation and that it likely has a time-sensitive “window of opportunity” for
its optimal effectiveness. 19 This time-sensitive window leads the author of this scholarly paper to
propose that Methylene Blue be administered prophylactically for prevention of post-CPB
hypotension rather than as a mere rescue alternative. The 2004 multicenter RCT by Levin et al.
infused half of their cohort of 56 patients that were afflicted by VS with 1.5mg/kg IV MB. In this
study, none of the participants from the experimental group perished and VS resolved within two
hours. On the other hand, 8 subjects from the control group experienced VS for more than 48
hours and 6 of these individuals died. 20 Lastly, the retrospective observational study by Mehaffey
et al. of 2017 assessed 118 subjects that received Methylene Blue after the onset of VS post-CPB.
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Two groups were specified: patients that received MB at the onset of VS (intraoperatively) and
patients that received treatment once admitted into an intensive care unit (ICU). The “early”
group had significantly lower rates of iatrogenic complications and mortality.21
DISCUSSION
“Administration of MB 1 hour preoperatively to patients at high risk of development of
vasoplegia raises SVR during the surgical period and lowers norepinephrine requirements.” 18
Maintenance of hemodynamic stability with Methylene Blue is statistically significant.
Approximately 0% of patients experience postoperative vasoplegia, while approximately 26% of
all patients without MB treatment experience the complication. 7 Through the years, Methylene
Blue has proven to be an effective treatment for refractory vasoplegia after the discontinuation of
cardiopulmonary bypass and it has a wide margin of safety. However, most of its use is limited to
last-line rescue therapy rather than prophylaxis. In fact, the number of studies in which the
pharmacological agent is used prophylactically is scarce.
Limitations for Research and Application
Further research about Methylene Blue for hypotension prophylaxis could be limited by
its potential adverse effects. Possibly the most infamous undesired effect of MB administration is
false low readings of pulse oximetry (SPO2). The blue dye of MB interferes with light absorption
and false SPO2 readings can last approximately 60 minutes after just one bolus. 7 This could deter
clinicians from adopting its widespread use because one would require arterial blood gas
sampling to verify true level of oxygenation in a patient, which could become tedious and timeconsuming. Another consideration that could limit future studies is that high doses of MB can
cause methemoglobinemia. 7 Additionally, MB has been linked to cardiac arrhythmias, coronary
vasoconstriction, decreased CO, decreased mesenteric and renal perfusion, and increased
pulmonary pressure. 14, 19 Lastly, administration of Methylene Blue to a patient with undiagnosed
glucose-6-phosphate dehydrogenase deficiency could be deleterious. In this patient population,
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hemolytic anemia can occur because of the body’s inability to metabolize MB into
leucomethylene. 22
CONCLUSION OF LITERATURE REVIEW
Methylene Blue is an old drug with great new potential. The pharmacological agent has
proven to be effective in the treatment of refractory hypotension after the discontinuation of
cardiopulmonary bypass, and it has a wide safety margin. Unfortunately, the number of studies
with a focus on prophylaxis are few. This is understandable as the patient populations that could
benefit from the treatment modality are at high risk for additional morbidity and mortality;
securing consent for experimental treatment for this demographic is challenging. Further testing,
however, should be carried on. 31% of all mortality in the world is attributed to cardiovascular
disease, yet MB is not a prominent agent of treatment. 1 As stated by Evora et al. after analyzing
decades’ worth of data on the matter, there is no standard when it comes to the dosage and timing
of administration of Methylene Blue, but the medical field could benefit greatly from the
development of practice guidelines. 19
IMPLEMENTATION of an EDUCATIONAL PROJECT
Goal
Various studies have proven that MB is effective at treating post-CPB VS and it is the
goal of this scholarly paper’s author to make clinicians consider MB as a prophylactic measure
more often, rather than just as a last resort. This objective lead to a new clinical question: can
anesthesia providers be influenced by an educational module to incorporate an unconventional
treatment modality, and administer prophylactic Methylene Blue to patients undergoing
cardiopulmonary bypass with the purpose of avoiding postoperative hypotension? The
participation of anesthesia providers was solicited for the purpose of answering this query.
Setting, Participants and Recruitment
The educational project was conducted virtually in its entirety. A PowerPoint
Presentation (PPT) was created which included the research findings from the literature reviewed.
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This presentation was uploaded and distributed via an online platform to members of a Floridian
anesthesia association; a clinical group comprised of CRNAs and Anesthesiologists that provide
anesthesia services to a hospital in Miami-Dade County. The roster was contacted via email and
participation was completely voluntary. The total number of participants was nine.
Description and Execution of the Project
The educational project was carried out through the web-based platform Qualtrics XM.
It consisted of a recruitment letter that specified expectations and details, a survey for the
collection of demographic data, a Pre-Test for the purpose of establishing baseline knowledge of
each clinician regarding Methylene Blue, the aforementioned PPT, and a Post-Test to determine
if any learning had taken place. The Post-Test also asked about the likelihood of each clinician to
incorporate MB into their own anesthetic practice.
Protection of Human Subjects
All anesthesia providers that accepted the invitation did so voluntarily and their
participation remained anonymous. Anonymity was ensured through randomized, unique
identification coding. Additionally, no personal identifiers were obtained at any point. All data
were secured on a password-protected laptop computer with malware and spyware protection. No
experimentation on any live human subjects was conducted on this undertaking. There was no
perceived risk for the participants and the estimated total time to complete the task was 20
minutes or less.
Data Management
The investigator for this clinical education endeavor is the Doctor of Nursing Practice
(DNP) candidate and author of this scholarly paper. The investigator is responsible for producing
the survey, tests, PPT, acquiring participants, protecting anonymity, analyzing data, and ensuring
the fidelity of the research. Statistical analysis is meant to evaluate baseline knowledge regarding
MB, determine whether learning occurred during the presentation, and ascertain if an educational
module can influence anesthetic practice.
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RESULTS from IMPLEMENTATION
Participant Demographics
Out of all participants, 5 (55.6%) were female and 4 (44.4%) were male. Ethnic
background resulted as follows: 1 (11.1%) Asian, 2 (22.2%) Caucasians, 5 (55.6%) Hispanics,
and 1 (11.1%) Other. Most clinicians had attained a Doctorate Degree – 7 (77.8%) – and they had
varying years of experience in anesthetic practice. 4 (44.4%) had one to two years of experience,
1 (11.1%) had three to five years, 1 (11.1%) had six to ten years, and 3 (33.3%) had over ten
years of experience.
Participant demographics are displayed below in Table 2.
Total Participants
Gender
Male
Female
Age
20 – 29
30 – 39
40 – 49
50 – 59
60+
Ethnicity
African American
Asian
Caucasian
Hispanic
Other
Level of Education
ASN
BSN
MSN
Doctorate
Years of Experience
1–2
3–5
6 – 10
10+

9
4 (44.4%)
5 (55.6%)
3 (33.3%)
2 (22.2%)
1 (11.1%)
0 (0%)
3 (33.3%)
0 (0%)
1 (11.1%)
2 (22.2%)
5 (55.6%)
1(11.1%)
0 (100%)
0 (100%)
2 (22.2%)
7 (77.8%)
4 (44.4%)
1 (11.1%)
1 (11.1%)
3 (33.3%)
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Pre-Test: Assessment of Baseline Knowledge
The Pre-Test for the purpose of determining each clinician’s baseline knowledge was
delivered prior to the PowerPoint Presentation and it was identical to the Post-Test at the
conclusion of the project. The format was a multiple choice-type questionnaire, and the questions
were as follows:
1. Approximately what percentage of all mortality is attributed to cardiovascular
disease?
2. The incidence of refractory hypotension after cardiopulmonary bypass ranges from:
3. Vasoplegic syndrome is characterized by:
4. Which factors increase the likelihood of refractory hypotension after
cardiopulmonary bypass?
5. Mortality rates for patients experiencing persistent vasoplegia for __ to __ hours
range from 25% to 28.6%:
6. Uses for Methylene Blue include:
7. How does Methylene Blue raise blood pressure?
8. Traditional treatment options for refractory hypotension that can occur after
separation of cardiopulmonary bypass include:
9. What is the recommended dosage of Methylene Blue for the treatment of
hypotension?
10. Methylene Blue can interfere with light absorption and result in false low readings on
pulse oximetry. How long can this effect last after just one bolus?
11. In what type of patient condition is Methylene Blue contraindicated?
12. How likely are you to use Methylene Blue prophylactically when providing
anesthesia services for patients undergoing cardiopulmonary bypass?
Regarding the twelfth question, 3 (33.3%) answered “unlikely”, 4 (44.4%) answered
“likely”, and 2 (22.2%) answered “highly likely”.
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Pre-Test results are displayed below in Table 3.
Participant #
#1
#2
#3
#4
#5
#6
#7
#8
#9

Correct Answers
6/11
8/11
3/11
7/11
8/11
5/11
1/11
6/11
6/11

Score
54.5%
72.7%
27.3%
63.6%
72.7%
45.5%
9.1%
54.5%
54.5%

Post-Test: Assessment of Learning
The Post-Test was presented after the PPT, and it was meant to determine if any learning
had occurred and if clinicians would be more open to incorporating Methylene Blue into their
own anesthetic practice. All participants attained a higher score when compared to their
performance on the Pre-Test. Furthermore, 6 (66.7%) of clinicians claimed that they would be
“likely” to add prophylactic MB to their repertoire in the context of post-CPB VS and 3 (33.3%)
stated that they would be “highly likely” to do so.

Post-Test results are displayed below in Table 4.
Participant #
#1
#2
#3
#4
#5
#6
#7
#8
#9

Correct Answers
9/11
11/11
5/11
11/11
9/11
11/11
11/11
11/11
11/11

Score
81.8%
100%
45.5%
100%
81.8%
100%
100%
100%
100%
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Table 5. Pre-Test vs Post-Test Scores
Participant #
#1
#2
#3
#4
#5
#6
#7
#8
#9

Pre-Test Score
54.5%
72.7%
27.3%
63.6%
72.7%
45.5%
9.1%
54.5%
54.5%

Post-Test Score
81.8%
100%
45.5%
100%
81.8%
100%
100%
100%
100%

Difference
+27.3%
+27.3%
+18.2%
+36.4%
+9.1%
+54.5%
+90.9%
+45.5%
+45.5%

IMPLEMENTATION DISCUSSION
The virtual project produced significant positive results. All participants attained higher
scores on the post-test when compared to the pre-test. On average, outcomes improved by 39.4%.
Also, the number of clinicians that would be “unlikely” to incorporate MB into their care of
patients undergoing cardiopulmonary bypass decreased from 33.3% to 0%. Lastly, those “likely”
to use MB prophylactically increased by 22.3% and those “highly likely” by 11.1%.
Limitations
The most glaring shortcoming of the process was its small sample size. The South Florida
anesthesia association that participated in this educational project currently has 42 active
anesthesia providers, yet only 9 clinicians took part from beginning to end. This anesthesia group
provides services for a facility with a dedicated cardiac surgical team, so an opportunity was
missed to potentially help influence future clinical practice. Another limitation was that all
interaction was web-based. Not only can an email invitation be easily overlooked, but also there
is no guarantee that partakers would complete the online module without distractions.
Implications for Future Anesthetic Practice
The extensive literature review has shown that Methylene Blue has great potential to
prevent hypotension after the discontinuation of cardiopulmonary bypass. However, the use of
MB is mostly reserved as a last-line rescue therapy. The pharmacological agent is seldom used
prophylactically and there are no standardized guidelines for dosage and timing. 19
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The educational project carried out by the author of this scholarly paper demonstrated
that anesthesia providers are willing to learn new ways to use an old drug. It also demonstrated
that they are open to adjusting their clinical practice in pursuit of the best possible patient
outcomes. It is worthwhile to conduct future research on Methylene Blue with a focus on
prophylaxis. New standardized guidelines could help decrease the incidence of morbidity and
mortality in the patient population in question, and decrease healthcare costs.
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Appendix A: Summary of Literature Review
Evaluation table 1
Citation

Leyh RG, Kofidis T, Strüber M, et al. Methylene blue: the drug of choice for
catecholamine-refractory vasoplegia after cardiopulmonary bypass? The Journal
of Thoracic and Cardiovascular Surgery. 2003;125(6):1426-1431.
doi:10.1016/s0022-5223(02)73284-4

Design/Method

This was an observational study with no control group. / 54 adult patients with
vasoplegia that was refractory to norepinephrine after CPB were administered 2
mg/kg of intravenous Methylene Blue. MB was administered over 20 minutes and
the effects on patient outcomes were then evaluated.

Sample/Setting

“Between October 2000 and October 2001, a total of 1,111 various operations
with CPB support were performed. In 4.8% of these cases (n = 54/1,111),
norepinephrine-refractory systemic vasoplegia developed.” Out of the 54 subjects,
41 were male, and the average age was 56.7 years. / Hannover, Germany

Major Variables
Studied and
Their Definitions

“Norepinephrine-refractory systemic vasoplegia: MAP < 60 mm Hg, CO > 4.0
L/min, SVR < 600 dynes”; MAP: average pressure in arteries during one cardiac
cycle; Mean pulmonary artery pressure; Mean right atrial pressure; Mean left
atrial pressure; CO: (cardiac output) amount of blood the heart pumps through the
circulatory system in a minute; SVR: (systemic vascular resistance) resistance to
blood flow by the systemic vasculature, excluding the pulmonary vasculature,
which the left ventricle has to overcome in order to perfuse the body

Measurement
and Data
Analysis

“Continuous variables are expressed as a mean  SD unless otherwise indicated.
The Friedman test was used for comparisons of means within the group.
Intragroup comparisons of values at sequential time points at different times were
done with the Wilcoxon test for nonnormally distributed data. Statistical
calculations were performed with the SPSS software package for Windows (SPSS
Inc, Chicago, Ill).”

Findings

MAP
before MB: 68  9, 1 h after MB: 72  12, 6 h after MB: 71  9, 12 h
after MB: 73  10.
MPAP
8

before MB: 23  6, 1 h after: 24  7, 6 h after: 25  5, 12 h after: 24 

MRAP
5

before MB: 14  4, 1 h after: 14  4, 6 h after: 15  4, 12 h after: 15 

MLAP
5

before MB: 11  4, 1 h after: 10  3, 6 h after: 12  5, 12 h after: 10 

CO
before MB: 7.6  3.1, 1 h after: 6.5  2.8, 6 h after: 6.1  2.4, 12 h after:
5.8  1.9
SVR
before MB: 547  108, 1 h after 766  194, 6 h after: 796  153, 12 h
after: 876  184
NE dose
before MB: 0.5 mcg/kg/min, 1 h after: 0.32 mcg/kg/min, 6 h after:
0.2 mcg/kg/min, 12 h after: 0.15mcg/kg/min
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Results

Methylene Blue was administered 136 minutes postoperatively and 51 minutes
after the start of a norepinephrine infusion to attain hemodynamic stability. In
every case, and infusion of Methylene Blue was initiated when a NE dosage of at
least 0.5 mcg/kg was reached. “Immediately after MB infusion, clinically
significant increases in MAP and SVR combined with a significant decrease in
NE dosage were seen in 92.4% of patients.” SVR increased while CO decreased,
but MPAP, MRAP, and MLAP were unaffected. Of note, none of the patients
experienced adverse effects related to MB administration.

Conclusions

“A single dose of methylene blue seems to be a potent approach to
norepinephrine-refractory vasoplegia after cardiopulmonary bypass for most
patients, with no obvious side effects. Guanylate cyclase inhibitors could be a
novel class of agents for the treatment of norepinephrine-refractory vasoplegia
after cardiopulmonary bypass.” A controlled clinical trial is now needed to
evaluate the role of methylene blue in this situation. “The favorable effect of MB
demonstrated in this study suggests that refractory vasoplegia after CPB may
reflect a dysregulation of nitric oxide synthesis and vascular smooth muscle cell
guanylate cyclase activation.” “The inhibition of the soluble guanylate cyclase
elicited by nitric oxide or any endothelially soluble guanylate cyclase activating
factor could be a novel approach in the treatment of norepinephrine-refractory
vasoplegia after CPB.”

Appraisal:
Worth to
Practice/Level

This observational study with no control group falls under the Level III category
of evidence. The evidence itself is strong, with consistent and compelling results.
/ This study is worthwhile because it deals with cardiovascular disease, which is a
major problem worldwide. Furthermore, positive and consistent results were
attained. An RCT should be conducted to determine if MB should be designated
as the drug of choice for post-CPB vasoplegia that is refractory to vasopressors.

Evaluation table 2
Citation

Cho JS, Song JW, Na S, Moon JH, Kwak YL. Effect of a single bolus of
methylene blue prophylaxis on vasopressor and transfusion requirement in
infective endocarditis patients undergoing cardiac surgery. Korean Journal of
Anesthesiology. 2012;63(2):142-148. doi:10.4097/kjae.2012.63.2.142

Design/Method

This was a “prospective, randomized and controlled trial.” / A total of 42 patients
were assigned randomly to the control group or the Methylene Blue group; 21
subjects received 2 mg/kg of Methylene Blue 20 minutes prior to the initiation of
cardiopulmonary bypass, and 21 subjects received saline 20 minutes prior to CPB.
The outcomes set for evaluation were vasopressor and transfusion requirements,
and hemodynamics.

Sample/Setting

A total of 42 adults with infective endocarditis that were scheduled for surgery
under cardiopulmonary bypass were selected and consented. Exclusionary criteria
consisted of active fever, leukocytosis, preexisting lung disease, severe liver or
kidney disease, CAD requiring surgical revascularization, and an ASA
classification greater than 4. The anesthesiologists and surgeons involved in the
surgeries were also blinded to the groups throughout the duration of the study.
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Major Variables
Studied and
Their Definitions

MBP: (mean arterial blood pressure) average pressure in the arteries during one
cardiac cycle; HR: (heart rate) number of heart beats in one minute; MPAP: mean
pulmonary artery pressure; CVP: (central venous pressure) blood pressure in the
vena cava near the right atrium; PCWP: (pulmonary wedge pressure) pressure
measured by wedging a pulmonary catheter with an inflated balloon into a
pulmonary artery; CI: (cardiac index) cardiac output in relation to total body
surface area; SVR: (systemic vascular resistance) resistance in the systemic
circulatory system which the left ventricle has to overcome in order to perfuse the
body; vasopressor requirements after CPB; and transfusion requirements after
CPB.

Measurement
and Data
Analysis

“All statistical analyses were performed using SPSS (SPSSFW, SPSS Inc.,
Chicago, IL, USA). The primary end point of this study was to evaluate the
amount of infused norepinephrine during and after CPB. A difference of 0.1
mcg/kg/min in the norepinephrine infusion rate between the groups was taken as
clinically significant. Based on the institutional results for IE patients who
underwent VHS, the standard deviation of norepinephrine infusion was 0.1
μg/kg/min. This calculation generated an estimated 18 patients in each group with
80% power and an alpha level of 0.05. Considering the 10% of drop- out rate, 20
patients in each group were enrolled. All data were expressed as the number of
patients or the mean ± SD. The normality of distribution was assessed using a q-q
plot and the Shapiro-Wilk test. Between-group data was compared by the X2 test,
Fisher’s exact test, independent t-test with post hoc comparison using the
Bonferroni test or Mann-Whitney U test with same post hoc comparison as
appropriate. Continuous variables were presented as mean ± SD or median
[interquartile range], and dichotomous variables were presented as number. A P
value < 0.05 was considered as significant.”

Findings

MBP control
68.2  12.5 (baseline), 67.8  11.2 20 (20 mins after CPB
weaning), 68.3  7.6 (at sternum closure), 77.6  13.7 (immediately after closure),
74.5  8.1 (12 after arrival at ICU)
MBP MB
72.4  10.1 (baseline), 61.7  10.8 (20 mins after CPB weaning),
64.3  6.4 (at sternum closure), 78.6  12.7 (immediately after closure), 76.1 
12.3 (12 into ICU stay)
HR control
78.4  14.1 (baseline), 91.2  12.9 (20 mins after CPB weaning),
95.2  12.5 (at sternum closure), 93.8  11.5 (immediately after closure), 85.6 
12.4 (12 hours into ICU stay)
HR MB
83.1  19.2 (baseline), 89.0  13.0 (20 mins after CPB weaning), 93.2
 15.2 (at sternum closure), 94.1  15.6 (immediately after closure), 85.2  12.8
(12 hours into ICU stay)
CVP control
8.5  3.8 (baseline), 8.5  2.3 (20 mins after CPB weaning), 9.8
 3.2 (at sternum closure), 7.7  3.0 (immediately after closure), 8.9  2.1 (12
hours into ICU stay)
CVP MB
9.3  4.7 (baseline), 9.3  1.7 (20 mins after CPB weaning), 10.5 
1.8 (at sternum closure), 9.1  2.9 (immediately after closure), 8.5  2.2 (12 hours
into ICU stay)
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MPAP control
24.9  10.2 (baseline), 18.9  4.1 (20 mins after CPB
weaning), 19.1  5.7 (at sternum closure), 18.1  3.5 (immediately after closure),
17.4  2.5 (12 hours into ICU stay)
MPAP MB
30.4  13.3 (baseline), 20.3  4.4 (20 mins after CPB weaning),
20.9  4.7 (at sternum closure), 20.3  6.4 (immediately after closure), 18.0  5.4
(12 hours into ICU stay)
PCWP control
18.3  7.7 (baseline), 13.7  3.7 (20 mins after CPB weaning),
14.7  3.4 (at sternum closure), 12.9  2.7 (immediately after closure), 12.7  2.1
(12 hours into ICU stay)
PCWP MB
22.5  11.2 (baseline), 14.7  4.0 (20 mins after CPB weaning),
15.3  4.4 (at sternum closure), 15.0  5.1 (immediately after closure), 13.5  4.8
(12 hours into ICU stay)
CI control
2.7  0.6 (baseline), 3.4  0.6 (20 mins after CPB weaning), 3.4 
0.7 (at sternum closure), 3.8  1.3 (immediately after closure), 3.3  0.7 (12 hours
into ICU stay)
CI MB
2.8  0.9 (baseline), 3.4  0.6 (20 mins after CPB weaning), 3.5  0.9
(at sternum closure), 3.5  1.0 (immediately after closure), 2.9  0.6 (12 hours
into ICU stay)
SVR control
1,175  318 (baseline), 916  268 (20 mins after CPB weaning),
948  249 (at sternum closure), 960  304 (immediately after closure), 1,071 
286 (12 hours into ICU stay)
SVR MB
1,185  376 (baseline), 843  326 (20 mins after CPB weaning), 870
 343 (at sternum closure), 1,085  540 (immediately after closure), 1,138  330
(12 hours into ICU stay)
NorEpi control (mcg/kg/min)
0.09 (immediately after CBP weaning), 0.06
(20 mins after CPB weaning), 0.07 (at sternum closure), 0.02 (immediately after
closure), 0 (12 hours into ICU stay)
NorEpi MB (mcg/kg/min)
0.06 (immediately after CPB weaning), 0.05 (20
mins after CPB weaning), 0 (at sternum closure), 0.02 (immediately after
closure), 0 (12 hours into ICU stay)
PRBC units transfused control

1.6  0.5

PRBC units transfused MB

4.6  4.0

FFP units transfused control
FFP units transfused MB

2.0  1.0
6.2  4.1

PLT units transfused control
PLT units transfused MB
Results

4.6  2.9

8

Differences in vasopressor requirements between the 2 groups were statistically
insignificant. The difference in transfusion requirement, however, was evident
within 24 hours postoperatively. The MB group required less blood product
transfusion than the control group.
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Conclusions

In this particular study, prophylactic administration of Methylene Blue did not
significantly reduce post-CPB vasopressor requirements. However, it did
noticeably reduce requirements of blood product transfusions. The authors
recognize that certain variables may have reduced the effectiveness of MB such
as the pathophysiology of infective endocarditis, and patient medications such as
ACE inhibitors perioperatively. Furthermore, there is no standardized protocol for
prevention of post-CBP vasoplegia in regard to Methylene Blue, and the authors
recommend that additional testing is called for.

Appraisal:
Worth to
Practice/Level

Randomized control trials fall under the Level I category of Evidence. This RCT
has good quality because it had adequate forms of control, an adequate sample
size, consistent results, fairly definitive conclusions, consistent recommendations,
and it included references to other scientific evidence. / This study has merit
because it pertains to cardiovascular disease, which is a major problem
worldwide. Further studies could lead to significant change in clinical practice for
a pharmacologic agent that has various proven benefits.

Evaluation table 3
Citation

Ozal E, Kuralay E, Yildirim V, et al. Preoperative methylene blue administration
in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann
Thorac Surg. 2005;79(5):1615-1619.

Design/Method

“This was a prospective randomized comparative study in which one group
received a single dose of MB in the preoperative period just before anesthesia and
another group did not.” The Methylene Blue group received an intravenous dose
of 2mg/kg of MB over 30 minutes 1 hour before the surgical procedure. The
control group was not subjected to such an intervention.

Sample/Setting

100 patients that were scheduled for CABG surgery on cardiopulmonary bypass
and that had additional risk factors for the development of post-CPB vasoplegia
were selected and consented. These risk factors were perioperative use of ACE
inhibitors, heparin, and calcium channel blockers; all of which are known
contributors to perioperative vasoplegia. Patients were assigned at random; 50 for
the control group and 50 for the MB group.

Major Variables
Studied and
Their Definitions

“Vasoplegic syndrome was defined as severe and persistent hypotension (mean
arterial pressure <50 mm Hg) occurring in the intraoperative period or in the early
postoperative period within 6 hours after weaning from CPB.” SVR: (systemic
vascular resistance) resistance in the systemic circulatory system which the left
ventricle has to overcome in order to perfuse the body; CO: (cardiac output)
amount of blood the heart pumps through the circulatory system in a minute; CI:
(cardiac index) cardiac output in relation to total body surface area; MAP: (mean
arterial pressure) average pressure in arteries during one cardiac cycle; CVP:
(central venous pressure) blood pressure in the vena cava near the right atrium;
PCWP: (pulmonary capillary wedge pressure) pressure measured by wedging a
pulmonary catheter with an inflated balloon into a pulmonary artery; MPAP:
mean pulmonary artery pressure
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Measurement
and Data
Analysis

Findings

“All statistical analyses were performed using the SPSS 10.0 Statistical program
for Windows (SPSS Inc, Chicago, IL). Continuous variables were expressed as
the mean  standard deviation. Differences between groups were tested for
significance using the Student’s t test or the Mann-Whitney U test. Categorical
variables were ex- pressed as percentages and analyzed using the x2 test or
Fisher’s exact test. Differences were considered significant when p < 0.05 was
determined by the two-tailed test.”
1,749.2  414.3

Volume infusion (mL) control
Volume infusion (mL) MB

1,577.0  329.4

NE (≥ 0.5 mcg/kg/min) control
NE (≥ 0.5 mcg/kg/min) MB

13 subjects
0 subjects

Inotropy required during CPB weaning control
Inotropy required during CPB weaning MB
Incidence of vasoplegia control
Incidence of vasoplegia MB

0 subjects

Incidence of NE-refractory VS MB

6 subjects

0 subjects

2.2  1.2 days

ICU stay control

1.2  0.5

Hospital stay control

8.4  2.0

Hospital stay MB

6.1  1.7

Mortality control

2 subjects

Mortality MB

7 subjects

13 subjects

Incidence on NE-refractory VS control

ICU stay MB

24 subjects

0 subjects

Results

When compared to the control group, the methylene blue group attained the
following benefits: significantly higher intraoperative SVR, significantly reduced
NE infusion requirements, lower incidence of required inotropic support,
decreased need for crystalloid and colloid infusions, and reduced ICU and
hospital length of stay.

Conclusions

The authors of this study achieved better hemodynamic stability and overall
clinical outcomes for patients undergoing cardiac surgery under cardiopulmonary
bypass with a single prophylactic dose of Methylene Blue (2 mg/kg of 1% MB).
These results were obtained without any adverse effects related to MB, and
despite multiple risk factors for VS in the patient population studied.

Appraisal:
Worth to
Practice/Level

Randomized control trials fall under the Level I category of Evidence. This RCT
has a high quality because it had adequate forms of control, an appropriate study
design and sample size, consistent results, definitive conclusions,
recommendations that are consistent with the findings, and it included references
to other scientific evidence. / This study has merit cardiovascular disease is a
major problem worldwide, and the vasoplegic syndrome that often develops after
CPB is associated with poor patient outcomes and prognosis. Furthermore, VS
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post-CPB leads to extended ICU and overall hospital length of stay. Further
studies at a larger scale could lead to significant change in clinical practice.
Evaluation Table 4
Citation

Maslow AD, Stearns G, Batula P, Schwartz CS, Gough J, Singh AK. The
hemodynamic effects of methylene blue when administered at the onset of
cardiopulmonary bypass. Anesthesia and Analgesia. 2006;103(1):2-8.

Design/Method

This was an RCT in which 30 adult patients scheduled for surgery on
cardiopulmonary bypass with the additional VS risk factor of perioperative use of
ACE inhibitors were selected and consented. Out of this group, half of the
subjects were randomly selected to receive 3 mg/kg of Methylene Blue
intravenously at the onset of CPB, while the other half would only receive saline.
The dose of MB or its equivalent volume if saline were administered after the
initiation of cardiopulmonary bypass (given a 5-minute window for patient
stabilization). Hemodynamic data was obtained at the cohort’s baseline; after
initiation of CPB, but before drug administration; 10 minutes after administration;
20 minutes after initial administration; 40 minutes after; 60 minutes after; and
post-CPB.

Sample/Setting

The 30 patients selected used ACE inhibitors perioperatively and were scheduled
for surgery under cardiopulmonary bypass. Exclusionary criteria included patients
that required vasopressor support before surgery, emergency procedures,
preexisting liver and renal disease, pH abnormalities, parturients, patients with a
history of hypersensitivity to MB, and patients with a G6PD deficiency.

Major Variables
Studied and
Their Definitions

MAP: (mean arterial blood pressure) average pressure in the arteries during one
cardiac cycle; HR: (heart rate) number of heart beats in one minute; MPAP: mean
pulmonary artery pressure; Mean right atrial pressure; PCWP: (pulmonary wedge
pressure) pressure measured by wedging a pulmonary catheter with an inflated
balloon into a pulmonary artery; CO: (cardiac output) amount of blood the heart
pumps through the circulatory system in a minute; SVR: (systemic vascular
resistance) resistance in the systemic circulatory system which the left ventricle
has to overcome in order to perfuse the body; and vasopressor requirements after
CPB

Measurement
and Data
Analysis

“Demographic variables are presented as number and percentage or mean, and
SD. Hemodynamic data are presented as the mean values and SD or occurrence
and percentage. Demographic, presurgical, surgical, and hemodynamic variables
were compared using Student’s t-tests, analysis of variance, or Fisher’s exact tests
for categorical and continuous data. Univariate analyses were performed to assess
the impact of perioperative variables on hemodynamic changes. P values <0.05
was considered as statistically significant. SAS v.8.2 (SAS Institute Inc., Cary,
NC) was used for the statistical analysis.”

Findings

MAP control
80 (baseline), 60 (CPB pre-drug), 55 (CPB post-drug), 57 (CPB
20 mins), 57 (CPB 40 mins), 58 (CPB 60 mins), 71 (post-CPB)
MAP MB
81 (baseline), 54 (CPB pre-drug), 63 (CPB post-drug), 60 (CPB 20
mins), 62 (CPB 40 min), 60 (CPB 60 mins), 72 (post-CPB
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HR control
HR MB

69 (baseline), 89 (post-CPB)
70 (baseline), 88 (post-CPB)

SVR control
1,399 (baseline), 975 (CPB pre-drug), 896 (CPB post-drug), 928
(CPB 20 mins), 922 (CPB 40 mins), 953 (CPB 60 mins), 916 (post-CPB)
SVR MB
1,440 (baseline), 841 (CPB pre-drug)m 986 (CPB post-drug), 939
(CPB 20 mins), 952 (CPB 40 mins), 946 (CPB 60 mins), 901 (post-CPB)
Phenylephrine control (mL/patient)
25.2 (21.0)
80% (post-drug), 73%
(CPB 20 mins), 53% (CPB 40 min), 60% (CPB 60 mins)
Phenylephrine MB (mL/patient)
1.8 (4.3)
mins), 7% (CPB 40 mins), 7% (CPB 60 mins)
Results

Conclusions

Appraisal:
Worth to
Practice/Level

0% (post-drug), 0% (CPB 20

The Methylene Blue group displayed increased SVR and MAP when compared to
the control group. The effect of the single bolus of MB had a duration of action of
40 minutes. On the other hand, the control group demonstrated less desirable
hemodynamic values throughout CPB and beyond. This group required more
frequent doses on phenylephrine while on pump and greater amounts of NE postCPB.
The authors of this study managed maintain adequate SVR and MAP in patients
undergoing cardiac surgery under cardiopulmonary bypass with a single
administration of 3 mg/kg of intravenous Methylene Blue. In doing so, they
managed to reduce the incidence and severity of VS post-CPB. The requirement
for post-operative vasopressors was reduced, and patients in the MB group
attained better clinical outcomes than the control group.
Randomized control trials fall under the Level I category of Evidence. This RCT
has good quality because it had adequate forms of control, an adequate sample
size, consistent results, fairly definitive conclusions, consistent recommendations,
and it included references to other scientific evidence. / This study has merit
because it pertains to cardiovascular disease, which is a major problem
worldwide, and promising results were attained. Further studies could lead to
significant change in clinical practice for a pharmacologic agent that has various
proven benefits.

Evaluation table 5
Citation

Evora, Paulo Roberto Barbosa, Alves Junior, Lafaiete, Ferreira, Cesar Augusto,
Menardi, Antônio Carlos, Bassetto, Solange, Rodrigues, Alfredo José, Scorzoni
Filho, Adilson, & Vicente, Walter Vilella de Andrade. (2015). Twenty years of
vasoplegic syndrome treatment in heart surgery. Methylene blue
revised. Brazilian Journal of Cardiovascular Surgery, 30(1), 84
92. https://doi.org/10.5935/1678-9741.20140115

Design/Method

This particular study is a literature review that analyzes articles regarding the use
of Methylene Blue in treatment of VS related to cardiac surgery. To retrieve the
data, the authors utilized the following search platforms: ISI WEB of Science,
SCOPUS, and Medline. Key words utilized in the search were: “Methylene blue
and heart surgery” or “Methylene Blue and cardiac surgery.”
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Sample/Setting

Major Variables
Studied and
Their Definitions

Measurement
and Data
Analysis

The articles reviewed span over 20 years of international publications. The
authors retrieved 58 publications related to the aforementioned topic that were
released between 1994 and 2009. Additionally, they retrieved 30 more articles
published between 2010 and 2014.
Vasoplegic syndrome “is a constellation of signs and symptoms: hypotension,
high cardiac index, low systemic vascular resistance, low filling pressures, diffuse
bleeding tendency, and sustained hypotension despite the use of high doses of
vasoconstrictor amines.” SVR: (systemic vascular resistance) resistance in the
systemic circulatory system which the left ventricle has to overcome in order to
perfuse the body; CO: (cardiac output) amount of blood the heart pumps through
the circulatory system in a minute; CI: (cardiac index) cardiac output in relation to
total body surface area; and MAP: (mean arterial pressure) average pressure in
arteries during one cardiac cycle

N/A

Findings

The authors discovered that the interest in Methylene Blue as a treatment option
for VS related to cardiac surgery has been steadily increasing over the past 5
years prior to their literature review.

Results

The authors reaffirmed the following concepts: the lethal dose of Methylene Blue
is 40 mg/kg (the traditional dose of 2 mg/kg is safe); MB is effective in cases of
up-regulation of Nitric Oxide; endothelial dysfunction is not caused by Methylene
Blue; MB works by inhibiting the cGMP pathway (it is not a vasoconstrictor
itself); after 40 minutes of a single bolus, MB plasma level decrease sharply; and
it is possible that MB has a “window of opportunity” for its effectiveness.

Conclusions

The benefits of Methylene Blue have been well documented over the years, but
there is no standard in regard to its dosage and timing of administration. It is
possible that the overall effectiveness of MB is time-sensitive, and further studies
are needed with the intention of developing a protocol.

Appraisal:
Worth to
Practice/Level

This literature review falls under the Level II category of evidence. The strength
of evidence is good and consistent, which calls for further studies. / This article
has merit because cardiovascular disease is a major problem worldwide, and the
vasoplegic syndrome that often develops after CPB is associated with poor patient
outcomes and prognosis. As the authors stated, there is no standard in regard to
dosage and timing of administration for MB. There is need for the establishment
prophylactic guidelines and determination of a therapeutic window.

Evaluation table 6
Citation

Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and
morbidity in vasoplegic patients after cardiac surgery. Annals of Thoracic
Surgery. 2004;77(2):496-499.

Design/Method

This was a multicenter RCT in which patients undergoing cardiac surgery with
cardiopulmonary bypass were selected and consented. The subjects with VS were
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randomly assigned to one of two groups; one group received 1.5 mg/kg of
intravenous Methylene Blue, and the other was the control group.
Sample/Setting

638 patients were initially included in the study, but only 56 of them met the
criteria of VS post-CPB. All subjects were scheduled for elective cardiac surgery
between 2001 and 2002.

Major Variables
Studied and
Their Definitions

“Vasoplegic syndrome was defined using the following criteria: hypotension,
mean arterial pressure less than 50 mm Hg, low filling pressures, central venous
pressure less than 10 mm Hg, normal or elevated cardiac index more than 2.5
L/m/m2, low peripheral resistance, less than 800 dyne/s/cm-5, and vasopressor
drug requirements.” MAP: (mean arterial pressure) average pressure in the
arteries during one cardiac cycle; CVP: (central venous pressure) blood pressure
in the vena cava near the right atrium; PCWP: (pulmonary wedge pressure)
pressure measured by wedging a pulmonary catheter with an inflated balloon into
a pulmonary artery; CI: (cardiac index) cardiac output in relation to total body
surface area; SVR: (systemic vascular resistance) resistance in the systemic
circulatory system which the left ventricle has to overcome in order to perfuse the
body; and vasopressor requirements.

Measurement
and Data
Analysis

“The differences between populations with and without VS (control group) were
analyzed as were those treated with MB and the placebo using the x2 test and
Fischer’s exact test for those categorical variables and the Student’s t test for
continuous variables. The relationship among variables is shown as odds ratio
(OR) of 95%. A p value lower than 0.05 was considered significant.”

Findings

Mortality control
Mortality MB

6 (21.4%)
0

Renal failure control

4 (14.3%)

Renal failure MB
Dialysis control
Dialysis MB

0
2 (7.1%)

0

Respiratory failure control
Respiratory failure MB
Liver failure control
Liver failure MB
CVA control
CVA MB

4 (14.3%)
0

3 (10.7%)
0

1 (3.6%)
0

Neumopathy control
Neumopathy MB

4 (14.3%)
0

SVT arrhythmia control
SVT arrhythmia MB

8 (28.6%)
2 (7.1%)

Ventricular arrhythmia control

3 (10.7%)
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Ventricular arrhythmia MB
Sepsis control
Sepsis MB

0

7 (25%)
0

Multi-organ dysfunction control
Multi-organ dysfunction MB

7 (25%)
0

Results

None of the patients in the MB group perished. Additionally, vasoplegia resolved
within 2 hours for all subjects in this group. On the other hand, 8 out of 28
patients in the control group remained vasoplegic beyond the 48-hour mark and 6
of those perished.

Conclusions

Out of the original 638 patients selected, only 56 met the criteria of post-CPB VS.
The control group demonstrated higher incidence of morbidity and mortality,
while the MB group reduced postop complications in this high-risk population.

Appraisal:
Worth to
Practice/Level

This randomized control trial falls under the Level I category of Evidence. This
RCT has good quality because it had adequate forms of control, an adequate
sample size, consistent results, fairly definitive conclusions, consistent
recommendations, and it included references to other scientific evidence. / This
study has merit because it pertains to cardiovascular disease, which is a major
problem worldwide. The mortality rate in the MB group was 0% and
postoperative complications were minimal. This study calls for further studies;
particularly for studies that target prevention rather than rescue therapy.

Evaluation table 7
Citation

Mehaffey JH, Johnston LE, Hawkins RB, et al. Methylene Blue for Vasoplegic
Syndrome After Cardiac Operation: Early Administration Improves Survival.
Annals of Thoracic Surgery. 2017;104(1):36-41.

Design/Method

This was a retrospective observational study with no control group. “All patients
that underwent cardiopulmonary bypass at our institution (Jan 1, 2011 to Jun 30,
2016) were identified through our Society of Thoracic Surgery database.
Pharmacy records identified patients receiving MB within 72 hours of
cardiopulmonary bypass. Multivariate logistic regression identified predictors of
major adverse events among patients receiving MB.”

Sample/Setting

Out of the 3,608 patients that underwent surgery under CPB in the
aforementioned time frame, only 118 subjects received MB treatment for VS
post-CPB.

Major Variables
Studied and
Their Definitions

The diagnosis of post-CPB vasoplegia “includes vasodilation characterized by
low SVR with elevated cardiac index (CI) resulting in hypotension despite high
doses of vasopressors on pump or postoperatively.” SVR: (systemic vascular
resistance) resistance in the systemic circulatory system which the left ventricle
has to overcome in order to perfuse the body; CO: (cardiac output) amount of
blood the heart pumps through the circulatory system in a minute; CI: (cardiac
index) cardiac output in relation to total body surface area; MAP: (mean arterial
pressure) average pressure in arteries during one cardiac cycle; MAE: major
adverse events; Early administration: intraoperatively; Late administration: in the
ICU setting; and vasopressor requirements.
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Measurement
and Data
Analysis

Findings

“The primary outcome was major adverse event (MAE) after administration of
MB for vasoplegic syndrome. MAEs included the STS major morbidities
(permanent stroke, renal failure, reoperation, deep sternal wound infection, and
prolonged ventilation) as well as operative mortality (in-hospital or 30-day).
Standard STS definitions were used for all variables, including new onset renal
failure and prolonged ventilation (>24 hours). In addition, preoperative and
intraoperative variables associated with MB treatment for vasoplegic syndrome
were assessed. Early administration was defined as operating room, and patients
not receiving MB until reaching the postoperative intensive care unit were
classified as late administration. Univariate analysis was performed using x2 and
Mann-Whitney U tests for categorical and continuous variables, respectively.
Multivariable logistic regression was used to identify risk-adjusted predictors of
MAEs in patients receiving MB for vasoplegic syndrome. SAS version 9.4 (SAS
Institute, Cary, NC) statistical soft- ware was used for analysis with a statistical
threshold for significance set at 0.05.”
Postop A Fib control
Postop A Fib MB
Stroke control
Stroke MB

725
27

71
6

Renal failure control
Renal failure MB

151
25

Deep sternal wound infection control
Deep sternal wound infection MB
Reoperation control
Reoperation MB

2
1

222
31

Prolonged ventilation control
Prolonged ventilation MB

232
27

Operative mortality control
Operative mortality MB

112
55

Major adverse event composite control
Major adverse events composite MB

516
55

Outcomes of MB administration for VS (early vs late)
Postop adverse event (early)

34

Postop adverse event (late)

53

Blood transfusion (early)
Blood transfusion (late)

44
58

Length of stay (days) (early)
Length of stay (days) (late)

12
12

37
Postop A Fib (early)
Postop A Fib (late)

14
13

Postop cardiac arrest (early)
Postop cardiac arrest (late)
Stroke (early)
Stroke (late)

5
8

2
4

Renal failure (early)

5

Renal failure (late)

20

Reoperation (early)
Reoperation (late)

10
21

Deep sternal wound infection (early)
Deep sternal wound infection (late)
Prolonged ventilation (early)
Prolonged ventilation (late)
STS major morbidity (late)
30-day mortality (late)

0

11
16

STS major morbidity (early)

30-day mortality (early)

1

17
37

5
20

Results

The group that was administered Methylene Blue intraoperatively at the onset of
VS had significantly lower rates of major adverse effects and eventual mortality.
The group that received treatment late (once admitted into the ICU) demonstrated
suboptimal results when compared to the early group.

Conclusions

The rate of morbidity and mortality in patients that experience VS post-CPB is
high. Methylene Blue has proven to ameliorate VS, and this study reinforced
postulations from other clinicians that MB has a “window of opportunity” in
regard to its maximum efficiency. In this study, early treatment with Methylene
Blue reduced the incidence of postop complications and improved that chance of
survival.

Appraisal:
Worth to
Practice/Level

This retrospective observational study falls under the Level III category of
evidence. The evidence itself seem promising, with consistent and compelling
results. / This study is worthwhile because it deals with cardiovascular disease,
which is a major problem worldwide. Furthermore, positive and consistent results
were attained. A prospective RCT should be the next step to definitively ascertain
the relationship between timing of administration and efficacy of Methylene blue
for refractory hypotension that often follows the period after cardiopulmonary
bypass.
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Appendix B: IRB Exemption Letter

Office of Research Integrity
Research Compliance, MARC 414
MEMORANDUM
To: Dr. Vicente Gonzalez
CC: Cesar Lopez
From: Elizabeth Juhasz, Ph.D., IRB Coordinator
Date: June 17, 2021
Protocol Title: “Prophylactic Administration of Methylene Blue to Surgical Patients to Prevent
Hypotension after Cardiopulmonary Bypass: An Educational Module for Anesthetic Practice”

The Florida International University Office of Research Integrity has reviewed your research
study for the use of human subjects and deemed it Exempt via the Exempt Review process.
IRB Protocol Exemption #: IRB-21-0248

IRB Exemption Date: 06/17/21

TOPAZ Reference #: 110237
As a requirement of IRB Exemption you are required to:
1) Submit an IRB Exempt Amendment Form for all proposed additions or changes in the
procedures involving human subjects. All additions and changes must be reviewed and approved
prior to implementation.
2) Promptly submit an IRB Exempt Event Report Form for every serious or unusual or
unanticipated adverse event, problems with the rights or welfare of the human subjects, and/or
deviations from the approved protocol.
3) Submit an IRB Exempt Project Completion Report Form when the study is finished or
discontinued.
Special Conditions: N/A
For further information, you may visit the IRB website at http://research.fiu.edu/irb.
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APPENDIX C: Recruitment Letter

March 1, 2021
Vicente Gonzalez, DNP, CRNA, APRN
Clinical Education Coordinator
Department of Nurse Anesthesiology Practice
Florida International University
Dr. Gonzalez
Thank you for inviting Mount Sinai Medical Center to participate in Doctor of Nursing Practice
(DNP) project conducted by Cesar Lopez entitled “Prophylactic Administration of Methylene
Blue to Surgical Patients to Prevent Hypotension after Cardiopulmonary Bypass: An Educational
Module” in the Nicole Wertheim College of Nursing and Health Sciences, Department of Nurse
Anesthetist Practice at Florida International University. I have warranted his permission to
conduct the project using our providers.
This project intends to evaluate if a structured education targeting providers will increase
knowledge on the use of Methylene Blue to prevent hypotension after cardio-pulmonary bypass.
Prior to the implementation of this educational project, the Florida International University
Institutional Review Board will evaluate and approve the procedures to conduct this project.
We understand the educational intervention will be via Qualtrics, with pretest and posttest
questionnaire, any data collected by Cesar Lopez is confidential and will be stored in a locked
filing cabinet at our office. We expect that Cesar Lopez will not interfere with normal hospital
performance, behaving in a professional manner and following standards of care.
We support the participation of our provides and staff in this project and look forward to working
with you.

Jampierre Mato, DNP, CRNA
Date: March 1, 2021
Executive CRNA Director
Miami Beach Anesthesiology Assoc.
Student Supervisor
FIU Dept. of Nurse Anesthetist Practice
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APPENDIX D: Educational Module Questionnaire

Pretest and Post-Test Questionnaire:
Prophylactic Administration of Methylene Blue to Surgical Patient to Prevent Hypotension
after Cardiopulmonary Bypass: An Educational Module for Anesthetic Practice
INTRODUCTION
The primary aim of this educational project is to improve the knowledge of anesthesia
providers pertaining to the role of Methylene Blue for patients that undergo cardiopulmonary
bypass. Please answer the questions below to the best of your ability. The questions either in
multiple choice or true/false format and are meant to measure knowledge and perceptions on the
use of Methylene Blue for refractory hypotension.
PERSONAL INFORMATION
1. Gender: Male
2. Age: 20 – 29

Female
30 – 39

Other
40 – 49

3. Ethnicity: African American

50 – 59

Asian

4. Level of Education: Associates

60+

Caucasian

Bachelors

Hispanic

Masters

Other

Doctorate

5. How many years have you been an anesthesia provider?
1 – 2 years

3 – 5 years

6 – 9 years

10+ years

QUESTIONNAIRE
1. Approximately what percentage of all mortality is attributed to cardiovascular
disease?
a. 11%
b. 21%
c. 31%
d. 41%
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2. The incidence of refractory hypotension after cardiopulmonary bypass ranges from:
a. 3% – 13%
b. 5% – 25%
c. 12% – 32%
d. 2% – 4%
3. Vasoplegic syndrome is characterized by:
a. Significant arterial hypotension, normal or high cardiac output, low systemic
resistance, increased vasopressor requirements, and increased requirement for
intravenous volume.
b. Significant arterial hypotension, heart rate > 90 beats/min, respiratory rate > 20
breaths/min, temperature > 38 C or < 36 C, increased vasopressor requirements.
c. Significant arterial hypotension, low cardiac output, low systemic vascular
resistance, increased nitric oxide production, decreased requirement for
intravenous volume.
d. Significant arterial hypertension, heart rate < 60 beats/min, irregular respiratory
pattern.
4. Which factors increase the likelihood of refractory hypotension after
cardiopulmonary bypass?
a. Perioperative use of beta-blockers
b. Preoperative use of angiotensin-converting enzyme inhibitors
c. Preoperative use of calcium channel blockers
d. Low ejection fractions
e. A, B, C
f.

All of the above

5. Mortality rates for patients experiencing persistent vasoplegia for ___ to ___ hours
range from 25% to 28.6%:
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a. 12 – 18
b. 24 – 36
c. 36 – 48
d. 72 – 96
6. Uses for Methylene Blue include:
a. Treatment of Methemoglobinemia
b. Surgical marker during urology procedures
c. Treatment of hypotension refractory to vasopressors
d. Identification of specific endocrine tissue
e. A, B
f.

All of the above

7. How does Methylene Blue raise blood pressure?
a. Direct alpha-adrenergic stimulation
b. Direct alpha-adrenergic and beta-adrenergic stimulation, and indirect release of
endogenous catecholamines
c. Prevention of smooth muscle vasodilation due to blockade of nitric oxide
synthase
d. Potentiation of guanylate cyclase that increases intracellular levels of cyclic CMP
8. Traditional treatment options for refractory hypotension that can occur after
separation of cardiopulmonary bypass include:
a. Phenylephrine infusion
b. Norepinephrine infusion
c. Crystalloid infusion
d. All of the above
e. None of the above
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9. What is the recommended dosage of Methylene Blue for the treatment of
hypotension?
a. 1mg/kg
b. 2mg/kg
c. 4mg/kg
d. 8mg/kg
10. Methylene Blue can interfere with light absorption and result in false low readings
on pulse oximetry. How long can this effect last after just one bolus?
a. 15 minutes
b. 30 minutes
c. 45 minutes
d. 60 minutes
e. 90 minutes
11. In which type of patient condition is Methylene Blue contraindicated?
a. Glucose-6-phosphate dehydrogenase deficiency
b. Pseudocholinesterase deficiency
c. Multiple Endocrine Neoplasia Type 1
d. Sepsis
12. How likely are you to use prophylactic Methylene Blue when providing anesthesia
services for patients undergoing cardiopulmonary bypass?
a. Highly likely
b. Likely
c. Unlikely
d. Highly unlikely
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